Search

Your search keyword '"Holly L Thacker"' showing total 5 results
Start Over Author "Holly L Thacker" Publisher bmj
5 results on '"Holly L Thacker"'

1. Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk

Author

Holly L. Thacker

Subjects
Geriatrics, Gynecology, medicine.medical_specialty, Postmenopausal women, business.industry, Osteoporosis, General Medicine, medicine.disease, Breast cancer, Disease risk, Medicine, Ischaemic heart disease, Raloxifene, business, medicine.drug
Abstract

Source Citation Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-37. 16837676

Published
2006
Full Text
View/download PDF

2. Review: oestrogen improves symptoms of overactive bladder in postmenopausal women

Author

Holly L. Thacker

Subjects
Gynecology, Geriatrics, medicine.medical_specialty, Postmenopausal women, Overactive bladder, business.industry, Estrogen, medicine.drug_class, MEDLINE, Medicine, General Medicine, business, medicine.disease
Abstract

Source Citation Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004;83:892-7. 15453881

Published
2005
Full Text
View/download PDF

3. Oestrogen therapy increased stroke risk and decreased hip fracture risk but did not affect coronary heart disease risk in postmenopausal women with prior hysterectomy

Author

Holly L Thacker

Subjects
medicine.medical_specialty, Hip fracture, Postmenopausal women, Hysterectomy, Framingham Risk Score, business.industry, medicine.medical_treatment, General Medicine, medicine.disease, Affect (psychology), Coronary heart disease, Surgery, Stroke risk, Internal medicine, medicine, business, Stroke
Published
2004
Full Text
View/download PDF

4. Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women

Author

Holly L Thacker

Subjects
Gynecology, medicine.medical_specialty, Intention-to-treat analysis, Hysterectomy, Progestogen, business.industry, medicine.medical_treatment, Incidence (epidemiology), Placebo-controlled study, General Medicine, Placebo, medicine.disease, Breast cancer, Medicine, Medroxyprogesterone acetate, business, medicine.drug
Abstract

(2003) JAMA 289, 3243. Chlebowski RT, Hendrix SL, Langer RD, et al. . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. . ; . : . –53 . [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] QUESTION: In postmenopausal women, does oestrogen plus progestogen hormone therapy (HT) increase the risk of abnormal mammographic results and diagnoses of breast cancer? Randomised (allocation concealed*), blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee),* placebo controlled trial with a mean 5.6 year follow up (Women’s Health Initiative [WHI]). 40 US clinical centres. 16 608 postmenopausal women who were 50–79 years of age (mean age 63.3 y). Exclusion criteria were previous hysterectomy, breast cancer, or probable survival

Published
2003
Full Text
View/download PDF

5. 17beta-estradiol reduced depressive and somatic symptoms in perimenopausal women

Author

Holly L. Thacker

Subjects
medicine.medical_specialty, Somatic cell, business.industry, Child and adolescent psychiatry, medicine, General Medicine, 17beta estradiol, Psychiatry, business
Abstract

Source Citation Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. A double-blind, randomized, placebo-controlled tri...

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results